NEW YORK – The stem cell and regenerative medicine industry is facing a serious funding problem. Just as the first therapies are reaching commercialization, biotechs in phase 2 and 3 are struggling to raise the funds needed to finish their studies. Over 300 biotechs, pharmas, investors, and suppliers will be meeting in Boston on September 20-21 at the Stem Cells USA and Regenerative Medicine Congress 2012.
The Stem Cells USA & Regenerative Medicine Congress is the region's largest commercial stem cells conference.
Most stem cell companies face two options - go bankrupt or find a partner with deep pockets. Despite there being hundreds of companies with promising technologies, most of them never pass Phase II trials due to lack of funding.
ALACHUA, FL May 16, 2012 - Florida Biologix®, a full-service biopharmaceutical development and contract manufacturing organization, provided cGMP manufacturing services to National Taiwan University Hospital under a contract signed in March 2008. Florida Biologix produced, purified, and tested a clinical batch of their novel gene therapy for a Phase I clinical trial of a rare genetic disease – AADC deficiency. The trial was led by Dr. Paul Wuh-Liang Hwu. Results of the clinical trial were published in the May 16th issue of Science Translational Medicine.
Roberts Biosolutions Ltd
Hillcoat Place, Edinburgh
United Kingdom
Email: info@genetherapyreview.com
Twitter: @gentherev
